KPX Lifescience.Co.Ltd (114450) - Total Assets
Based on the latest financial reports, KPX Lifescience.Co.Ltd (114450) holds total assets worth ₩50.34 Billion KRW (≈ $34.12 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check cash flow reinvestment rate of KPX Lifescience.Co.Ltd to assess the company's total reinvestment commitment from operating cash flow.
KPX Lifescience.Co.Ltd - Total Assets Trend (2014–2024)
This chart illustrates how KPX Lifescience.Co.Ltd's total assets have evolved over time, based on quarterly financial data. Explore how much of KPX Lifescience.Co.Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
KPX Lifescience.Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
KPX Lifescience.Co.Ltd's total assets of ₩50.34 Billion consist of 48.9% current assets and 51.1% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩9.07 Billion | 20.2% |
| Accounts Receivable | ₩5.02 Billion | 11.2% |
| Inventory | ₩3.91 Billion | 8.7% |
| Property, Plant & Equipment | ₩13.53 Billion | 30.1% |
| Intangible Assets | ₩109.40 Million | 0.2% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how KPX Lifescience.Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KPX Lifescience.Co.Ltd (114450) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: KPX Lifescience.Co.Ltd's current assets represent 48.9% of total assets in 2024, an increase from 40.3% in 2014.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2024, up from 4.6% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2014.
- Asset Diversification: The largest asset category is property, plant & equipment at 30.1% of total assets.
KPX Lifescience.Co.Ltd Competitors by Total Assets
Key competitors of KPX Lifescience.Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩222.34 Billion |
|
Caregen Co.Ltd
KQ:214370
|
Korea | ₩233.98 Billion |
|
Kolon Life Science Inc
KQ:102940
|
Korea | ₩642.14 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩98.92 Billion |
|
Komipharm International Co. Ltd
KQ:041960
|
Korea | ₩133.92 Billion |
KPX Lifescience.Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.90 | 2.96 | 2.28 |
| Quick Ratio | 1.52 | 2.30 | 1.66 |
| Cash Ratio | 0.00 | 1.08 | 0.00 |
| Working Capital | ₩12.77 Billion | ₩13.54 Billion | ₩13.79 Billion |
KPX Lifescience.Co.Ltd - Advanced Valuation Insights
This section examines the relationship between KPX Lifescience.Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.62 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.6% |
| Total Assets | ₩44.97 Billion |
| Market Capitalization | $22.01 Million USD |
Valuation Analysis
Below Book Valuation: The market values KPX Lifescience.Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: KPX Lifescience.Co.Ltd's assets grew by 2.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for KPX Lifescience.Co.Ltd (2014–2024)
The table below shows the annual total assets of KPX Lifescience.Co.Ltd from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩44.97 Billion ≈ $30.48 Million |
+2.61% |
| 2023-12-31 | ₩43.83 Billion ≈ $29.70 Million |
-29.80% |
| 2022-12-31 | ₩62.43 Billion ≈ $42.31 Million |
-13.26% |
| 2021-12-31 | ₩71.98 Billion ≈ $48.78 Million |
+1.60% |
| 2020-12-31 | ₩70.85 Billion ≈ $48.01 Million |
-1.46% |
| 2019-12-31 | ₩71.89 Billion ≈ $48.72 Million |
+3.64% |
| 2018-12-31 | ₩69.37 Billion ≈ $47.01 Million |
-4.92% |
| 2017-12-31 | ₩72.96 Billion ≈ $49.45 Million |
-5.31% |
| 2016-12-31 | ₩77.06 Billion ≈ $52.22 Million |
+14.76% |
| 2015-12-31 | ₩67.15 Billion ≈ $45.51 Million |
+1.08% |
| 2014-12-31 | ₩66.43 Billion ≈ $45.02 Million |
-- |
About KPX Lifescience.Co.Ltd
KPX Lifescience.Co.,Ltd. engages in development, production, and sale of agrochemical raw materials and pharmaceutical intermediates in South Korea and internationally. The company offers raw materials for pharmaceuticals, pesticides, and primary intermediates to the pharmaceutical and agrochemical markets. It also develops EDP-CL, an intermediate for piperacillin-based antibiotics, including N,N… Read more